Diabetes Care, Vol 23, Issue 11 1666-1671, Copyright © 2000 by American Diabetes Association

ARTICLES

A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes

P Raskin, L Klaff, R Bergenstal, JP Halle, D Donley and T Mecca
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas 75930-8853, USA.

OBJECTIVE: To determine the safety and efficacy of the long-acting insulin analog, insulin glargine, as a component of basal bolus therapy in patients with type 1 diabetes. RESEARCH DESIGN AND METHODS: Patients with type 1 diabetes receiving basal-bolus insulin treatment with NPH human insulin and insulin lispro were randomized to receive insulin glargine (HOE 901), a long-acting basal insulin analog, once a day (n = 310) or NPH human insulin (n = 309) as basal treatment with continued bolus insulin lispro for 16 weeks in an open-label study NPH insulin patients maintained their prior schedule of administration once or twice a day, whereas insulin glargine patients received basal insulin once a day at bedtime. RESULTS: Compared with all NPH insulin patients, insulin glargine patients had significant decreases in fasting blood glucose measured at home (means +/- SEM, -42.0 +/- 4.7 vs. -12.4 +/- 4.7 mg/dl [-2.33 +/- 0.26 vs. -0.69 +/- 0.26 mmol/l]; P = 0.0001). These differences were evident early and persisted throughout the study More patients in the insulin glargine group (29.6%) than in the NPH group (16.8%) reached a target fasting blood glucose of 119 mg/dl (< 6.6 mmol/l). However, there were no differences between the groups with respect to change in GHb. Insulin glargine treatment was also associated with a significant decrease in the variability of fasting blood glucose values (P = 0.0124). No differences in the occurrence of symptomatic hypoglycemia, including nocturnal hypoglycemia, were observed. Overall, adverse events were similar in the two treatment groups with the exception of injection site pain, which was more common in the insulin glargine group (6.1%) than in the NPH group (0.3%). Weight gain was 0.12 kg in insulin glargine patients and 0.54 kg in NPH insulin patients (P = 0.034). CONCLUSIONS: Basal insulin therapy with insulin glargine once a day appears to be as safe and at least as effective as using NPH insulin once or twice a day in maintaining glycemic control in patients with type 1 diabetes receiving basal-bolus insulin treatment with insulin lispro.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. J. Fowler Hypoglycemia Clin. Diabetes, October 1, 2008; 26(4): 170 - 173. [Full Text] [PDF]

				I. Hartman Insulin Analogs: Impact on Treatment Success, Satisfaction, Quality of Life, and Adherence Clin. Med. Res., September 1, 2008; 6(2): 54 - 67. [Abstract] [Full Text] [PDF]

				R. M. Bergenstal, M. Johnson, M. A. Powers, A. Wynne, A. Vlajnic, P. Hollander, and M. Rendell Adjust to Target in Type 2 Diabetes: Comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine Diabetes Care, July 1, 2008; 31(7): 1305 - 1310. [Abstract] [Full Text] [PDF]

				K. Hassan, L. M. Rodriguez, S. E. Johnson, S. Tadlock, and R. A. Heptulla A Randomized, Controlled Trial Comparing Twice-a-Day Insulin Glargine Mixed With Rapid-Acting Insulin Analogs Versus Standard Neutral Protamine Hagedorn (NPH) Therapy in Newly Diagnosed Type 1 Diabetes Pediatrics, March 1, 2008; 121(3): e466 - e472. [Abstract] [Full Text] [PDF]

				J. C. Pickup and E. Renard Long-Acting Insulin Analogs Versus Insulin Pump Therapy for the Treatment of Type 1 and Type 2 Diabetes Diabetes Care, February 1, 2008; 31(Supplement_2): S140 - S145. [Abstract] [Full Text] [PDF]

				A. L. Trujillo Insulin Analogs and Pregnancy Diabetes Spectr, April 1, 2007; 20(2): 94 - 101. [Abstract] [Full Text] [PDF]

				T. N. Erickson, E. B. Devine, T. S. O'Young, L. J. Hanson, B. French, and C. Brennan Effect of switching medically vulnerable patients with uncontrolled diabetes from isophane insulin human to insulin glargine. Am. J. Health Syst. Pharm., October 1, 2006; 63(19): 1862 - 1871. [Abstract] [Full Text] [PDF]

				V. Cherubini, A. Iannilli, D. Iafusco, F. Cardella, M. S. Giamprini, C. Fanelli, and G. V. Coppa Premeal Insulin Treatment During Basal-Bolus Regimen in Young Children With Type 1 Diabetes Diabetes Care, October 1, 2006; 29(10): 2311 - 2312. [Full Text] [PDF]

				F. M Regan and D. B Dunger Use of new insulins in children Arch. Dis. Child. Ed. Pract., August 1, 2006; 91(2): ep47 - ep53. [Full Text] [PDF]

				A. T. Soliman, M. Omar, M. M. Rizk, A. El Awwa, and F. M. AlGhobashy Glycaemic Control with Modified Intensive Insulin Injections (MII) Using Insulin Pens and Premixed Insulin in Children with Type-1 Diabetes: A Randomized Controlled Trial J Trop Pediatr, August 1, 2006; 52(4): 276 - 281. [Abstract] [Full Text] [PDF]

				J. C. Pickup Point: Are Insulin Pumps Underutilized in Type 1 Diabetes? Yes. Diabetes Care, June 1, 2006; 29(6): 1449 - 1452. [Full Text] [PDF]

				Z. T. Bloomgarden Insulin Treatment and Type 1 Diabetes Topics Diabetes Care, April 1, 2006; 29(4): 936 - 944. [Full Text] [PDF]

				I. B. Hirsch, B. W. Bode, S. Garg, W. S. Lane, A. Sussman, P. Hu, O. M. Santiago, J. W. Kolaczynski, and for the Insulin Aspart CSII/MDI Comparison Study G Continuous Subcutaneous Insulin Infusion (CSII) of Insulin Aspart Versus Multiple Daily Injection of Insulin Aspart/Insulin Glargine in Type 1 Diabetic Patients Previously Treated With CSII Diabetes Care, March 1, 2005; 28(3): 533 - 538. [Abstract] [Full Text] [PDF]

				I. B. Hirsch Insulin Analogues N. Engl. J. Med., January 13, 2005; 352(2): 174 - 183. [Full Text] [PDF]

				Y. C. Kudva, A. Basu, G. D. Jenkins, G. M. Pons, L. L. Quandt, J. A. Gebel, D. A. Vogelsang, S. A. Smith, R. A. Rizza, and W. L. Isley Randomized Controlled Clinical Trial of Glargine Versus Ultralente Insulin in the Treatment of Type 1 Diabetes Diabetes Care, January 1, 2005; 28(1): 10 - 14. [Abstract] [Full Text] [PDF]

				I. Gallen Review: The evolution of insulin treatment in type 1 diabetes: the advent of analogues The British Journal of Diabetes & Vascular Disease, November 1, 2004; 4(6): 378 - 381. [Abstract] [PDF]

				Update on insulin analogues DTB, October 1, 2004; 42(10): 77 - 80. [Abstract] [Full Text] [PDF]

				K. K. Daugherty Review of Insulin Therapy Journal of Pharmacy Practice, February 1, 2004; 17(1): 10 - 19. [Abstract] [PDF]

				E. S. Albright, R. Desmond, and D. S.H. Bell Efficacy of Conversion From Bedtime NPH Insulin Injection to Once- or Twice-Daily Injections of Insulin Glargine in Type 1 Diabetic Patients Using Basal/Bolus Therapy Diabetes Care, February 1, 2004; 27(2): 632 - 633. [Full Text] [PDF]

				C. L Acerini and A. Deeb Review: New approaches to insulin therapy in children and adolescents with type 1 diabetes The British Journal of Diabetes & Vascular Disease, January 1, 2004; 4(1): 16 - 20. [Abstract] [PDF]

				I. W. Gallen and C. Carter Prospective Audit of the Introduction of Insulin Glargine (Lantus) Into Clinical Practice in Type 1 Diabetic Patients Diabetes Care, December 1, 2003; 26(12): 3352 - 3353. [Full Text] [PDF]

				A. Hamann, S. Matthaei, C. Rosak, and L. Silvestre A Randomized Clinical Trial Comparing Breakfast, Dinner, or Bedtime Administration of Insulin Glargine in Patients With Type 1 Diabetes Diabetes Care, June 1, 2003; 26(6): 1738 - 1744. [Abstract] [Full Text] [PDF]

				D. E. DeWitt and I. B. Hirsch Outpatient Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus: Scientific Review JAMA, May 7, 2003; 289(17): 2254 - 2264. [Abstract] [Full Text] [PDF]

				A. D. Morris Addressing Dosing Frequency in Diabetes: A Simple Approach to Improving Adherence to Therapy and Clinical Outcomes The Diabetes Educator, May 1, 2003; 29(3): 440 - 453. [PDF]

				P. Rossetti, S. Pampanelli, C. Fanelli, F. Porcellati, E. Costa, E. Torlone, L. Scionti, and G. B. Bolli Intensive Replacement of Basal Insulin in Patients With Type 1 Diabetes Given Rapid-Acting Insulin Analog at Mealtime: A 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime Diabetes Care, May 1, 2003; 26(5): 1490 - 1496. [Abstract] [Full Text] [PDF]

				P. Vague, J.-L. Selam, S. Skeie, I. De Leeuw, J. W.F. Elte, H. Haahr, A. Kristensen, and E. Draeger Insulin Detemir Is Associated With More Predictable Glycemic Control and Reduced Risk of Hypoglycemia Than NPH Insulin in Patients With Type 1 Diabetes on a Basal-Bolus Regimen With Premeal Insulin Aspart Diabetes Care, March 1, 2003; 26(3): 590 - 596. [Abstract] [Full Text] [PDF]

				N. P. Murphy, S. M. Keane, K. K. Ong, M. Ford-Adams, J. A. Edge, C. L. Acerini, and D. B. Dunger Randomized Cross-Over Trial of Insulin Glargine Plus Lispro or NPH Insulin Plus Regular Human Insulin in Adolescents With Type 1 Diabetes on Intensive Insulin Regimens Diabetes Care, March 1, 2003; 26(3): 799 - 804. [Abstract] [Full Text] [PDF]

				N. Younis, H. Soran, and D. Bowen-Jones Insulin glargine: a new basal insulin analogue QJM, November 1, 2002; 95(11): 757 - 761. [Full Text] [PDF]

				J. H. DeVries, F. J. Snoek, P. J. Kostense, N. Masurel, and R. J. Heine A Randomized Trial of Continuous Subcutaneous Insulin Infusion and Intensive Injection Therapy in Type 1 Diabetes for Patients With Long-Standing Poor Glycemic Control Diabetes Care, November 1, 2002; 25(11): 2074 - 2080. [Abstract] [Full Text] [PDF]

				D. R. Owens Optimising glycaemic control -- the role of long-acting insulin analogues in basal insulin therapy The British Journal of Diabetes & Vascular Disease, September 1, 2002; 2(5): 403 - 406. [Abstract] [PDF]

				A. W. Norris and L. M.B. Laffel Avoiding Nocturnal Hypoglycemia: Consideration of an Extra Injection at Bedtime Ann Intern Med, April 2, 2002; 136(7): 547 - 549. [Full Text] [PDF]

				Use of a New Long-Acting Insulin in Type 1 Diabetes Journal Watch (General), December 5, 2000; 2000(1205): 4 - 4. [Full Text]